Please enable JavaScript to continue using this application.

Compare $PLX vs $STRO | Chartloom

Compare

$PLX vs $STRO

Protalix Biotherapeutics Inc · Sutro Biopharma Inc

PLX

Protalix Biotherapeutics Inc

STRO

Sutro Biopharma Inc

Compare $PLX vs $STRO

Comparing Protalix Biotherapeutics Inc and Sutro Biopharma Inc

PLXProtalix Biotherapeutics Inc

STROSutro Biopharma Inc

PLXProtalix Biotherapeutics Inc

Market cap

$224M

P/E (TTM)

12.11x

Forward P/E (NTM)

—

Forward P/S (NTM)

3.56x

Rev growth (TTM)

30.1%

YTD performance

59.8%

52W performance

8.2%

FCF yield

3.4%

STROSutro Biopharma Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.01x

Rev growth (TTM)

-56.3%

YTD performance

30.2%

52W performance

67.2%

FCF yield

-61.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PLX

STRO

Detailed metrics comparison

PLX

Protalix Biotherapeutics Inc

STRO

Sutro Biopharma Inc

Market Cap

PLX$224M

STRO$236M

Enterprise Value

PLX$197M

STRO$421M

Price

PLX$2.78

STRO$14.27

P/E Ratio

PLX12.11x

STRON/A

P/S Ratio

PLX2.78x

STRO5.17x

EV/Sales

PLX2.44x

STRO9.22x

EV/EBITDA

PLX7.37x

STRO0.00x

P/B Ratio

PLX3.06x

STRO5.78x

P/FCF Ratio

PLX29.21x

STRON/A

EV/FCF

PLX25.63x

STRO-2.89x

PEG Ratio

PLX0.06x

STRON/A

Forward P/E (NTM)

PLXN/A

STRON/A

Forward P/S (NTM)

PLX3.56x

STRO6.01x

Revenue (TTM)

PLX$81M

STRO$46M

Revenue Growth (YoY)

PLX30.1%

STRO-56.3%

Forward Rev Growth

PLX-19.1%

STRO-19.2%

Gross Margin (TTM)

PLX69.2%

STRO0.0%

Operating Margin (TTM)

PLX28.9%

STRO0.0%

EBITDA Margin (TTM)

PLX30.8%

STRO-275.3%

Net Margin (TTM)

PLX23.5%

STRO-395.2%

FCF Margin (TTM)

PLX9.5%

STRO-318.6%

Net Income (TTM)

PLX$19M

STRO$-181M

FCF (TTM)

PLX$8M

STRO$-146M

EPS (TTM)

PLX$0.23

STRO-$10.90

ROE (TTM)

PLX31.6%

STRO-22384.0%

ROA (TTM)

PLX20.1%

STRO-8812.0%

ROIC (TTM)

PLX31.6%

STRO-22384.0%

Cash

PLX$27M

STRO$54M

Debt

PLX$0

STRO$239M

Net Cash/Debt

PLX$27M

STRO$-185M

Current Ratio (TTM)

PLX2.94x

STRO3.32x

Quick Ratio (TTM)

PLX1.91x

STRO3.22x

Debt/Equity (TTM)

PLX0.00x

STRO4.05x

Debt/Assets (TTM)

PLX0.0%

STRO0.0%

Interest Coverage (TTM)

PLXN/A

STRON/A

Net Debt/EBITDA (TTM)

PLX0.00x

STRO0.00x

Beta

PLX-0.05

STRO1.47

52W Performance

PLX8.2%

STRO67.2%

YTD Performance

PLX59.8%

STRO30.2%

% from 52W High

PLX-12.9%

STRO-67.5%

% from 52W Low

PLX73.7%

STRO99.6%

Asset Turnover (TTM)

PLX0.85x

STRO0.22x

FCF Yield (TTM)

PLX3.4%

STRO-61.6%

Earnings Yield (TTM)

PLX8.5%

STRO-76.4%

Dividend Yield (TTM)

PLXN/A

STRON/A

Rule of 40

PLX39.7

STRO-374.9

EV/GP/RG

PLXN/A

STRON/A

Ticker research

View PLX research View STRO research

Metric	PLX Protalix Biotherapeutics Inc	STRO Sutro Biopharma Inc
Market & Valuation
Market Cap	$224M	$236M
Enterprise Value	$197M	$421M
Price	$2.78	$14.27
P/E Ratio	12.11x	N/A
P/S Ratio	2.78x	5.17x
EV/Sales	2.44x	9.22x
EV/EBITDA	7.37x	0.00x
P/B Ratio	3.06x	5.78x
P/FCF Ratio	29.21x	N/A
EV/FCF	25.63x	-2.89x
PEG Ratio	0.06x	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.56x	6.01x
Revenue & Growth
Revenue (TTM)	$81M	$46M
Revenue Growth (YoY)	30.1%	-56.3%
Forward Rev Growth	-19.1%	-19.2%
Profitability
Gross Margin (TTM)	69.2%	0.0%
Operating Margin (TTM)	28.9%	0.0%
EBITDA Margin (TTM)	30.8%	-275.3%
Net Margin (TTM)	23.5%	-395.2%
FCF Margin (TTM)	9.5%	-318.6%
Net Income (TTM)	$19M	$-181M
FCF (TTM)	$8M	$-146M
EPS (TTM)	$0.23	-$10.90
ROE (TTM)	31.6%	-22384.0%
ROA (TTM)	20.1%	-8812.0%
ROIC (TTM)	31.6%	-22384.0%
Financial Health
Cash	$27M	$54M
Debt	$0	$239M
Net Cash/Debt	$27M	$-185M
Current Ratio (TTM)	2.94x	3.32x
Quick Ratio (TTM)	1.91x	3.22x
Debt/Equity (TTM)	0.00x	4.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.05	1.47
52W Performance	8.2%	67.2%
YTD Performance	59.8%	30.2%
% from 52W High	-12.9%	-67.5%
% from 52W Low	73.7%	99.6%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.22x
FCF Yield (TTM)	3.4%	-61.6%
Earnings Yield (TTM)	8.5%	-76.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	39.7	-374.9
EV/GP/RG	N/A	N/A
Ticker research	View PLX research	View STRO research

Valuation

P/E Ratio

PLX

12.11x

P/S Ratio

PLX

2.78x

STRO

5.17x

EV/FCF

STRO

-2.89x

PLX

25.63x

Growth & revenue

Revenue Growth TTM

PLX

30.1%

STRO

-56.3%

Forward Revenue Growth

PLX

-19.1%

STRO

-19.2%

Profitability & performance

Gross Margin

PLX

69.2%

STRO

0.0%

ROE

PLX

31.6%

STRO

-22384.0%

FCF Yield %

PLX

3.4%

STRO

-61.6%

52-Week Performance

STRO

67.2%

PLX

8.2%

Detailed metrics comparison

PLX

Protalix Biotherapeutics Inc

STRO

Sutro Biopharma Inc

Market Cap

PLX$224M

STRO$236M

Enterprise Value

PLX$197M

STRO$421M

Price

PLX$2.78

STRO$14.27

P/E Ratio

PLX12.11x

STRON/A

P/S Ratio

PLX2.78x

STRO5.17x

EV/Sales

PLX2.44x

STRO9.22x

EV/EBITDA

PLX7.37x

STRO0.00x

P/B Ratio

PLX3.06x

STRO5.78x

P/FCF Ratio

PLX29.21x

STRON/A

EV/FCF

PLX25.63x

STRO-2.89x

PEG Ratio

PLX0.06x

STRON/A

Forward P/E (NTM)

PLXN/A

STRON/A

Forward P/S (NTM)

PLX3.56x

STRO6.01x

Revenue (TTM)

PLX$81M

STRO$46M

Revenue Growth (YoY)

PLX30.1%

STRO-56.3%

Forward Rev Growth

PLX-19.1%

STRO-19.2%

Gross Margin (TTM)

PLX69.2%

STRO0.0%

Operating Margin (TTM)

PLX28.9%

STRO0.0%

EBITDA Margin (TTM)

PLX30.8%

STRO-275.3%

Net Margin (TTM)

PLX23.5%

STRO-395.2%

FCF Margin (TTM)

PLX9.5%

STRO-318.6%

Net Income (TTM)

PLX$19M

STRO$-181M

FCF (TTM)

PLX$8M

STRO$-146M

EPS (TTM)

PLX$0.23

STRO-$10.90

ROE (TTM)

PLX31.6%

STRO-22384.0%

ROA (TTM)

PLX20.1%

STRO-8812.0%

ROIC (TTM)

PLX31.6%

STRO-22384.0%

Cash

PLX$27M

STRO$54M

Debt

PLX$0

STRO$239M

Net Cash/Debt

PLX$27M

STRO$-185M

Current Ratio (TTM)

PLX2.94x

STRO3.32x

Quick Ratio (TTM)

PLX1.91x

STRO3.22x

Debt/Equity (TTM)

PLX0.00x

STRO4.05x

Debt/Assets (TTM)

PLX0.0%

STRO0.0%

Interest Coverage (TTM)

PLXN/A

STRON/A

Net Debt/EBITDA (TTM)

PLX0.00x

STRO0.00x

Beta

PLX-0.05

STRO1.47

52W Performance

PLX8.2%

STRO67.2%

YTD Performance

PLX59.8%

STRO30.2%

% from 52W High

PLX-12.9%

STRO-67.5%

% from 52W Low

PLX73.7%

STRO99.6%

Asset Turnover (TTM)

PLX0.85x

STRO0.22x

FCF Yield (TTM)

PLX3.4%

STRO-61.6%

Earnings Yield (TTM)

PLX8.5%

STRO-76.4%

Dividend Yield (TTM)

PLXN/A

STRON/A

Rule of 40

PLX39.7

STRO-374.9

EV/GP/RG

PLXN/A

STRON/A

Ticker research

View PLX research View STRO research

Metric	PLX Protalix Biotherapeutics Inc	STRO Sutro Biopharma Inc
Market & Valuation
Market Cap	$224M	$236M
Enterprise Value	$197M	$421M
Price	$2.78	$14.27
P/E Ratio	12.11x	N/A
P/S Ratio	2.78x	5.17x
EV/Sales	2.44x	9.22x
EV/EBITDA	7.37x	0.00x
P/B Ratio	3.06x	5.78x
P/FCF Ratio	29.21x	N/A
EV/FCF	25.63x	-2.89x
PEG Ratio	0.06x	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.56x	6.01x
Revenue & Growth
Revenue (TTM)	$81M	$46M
Revenue Growth (YoY)	30.1%	-56.3%
Forward Rev Growth	-19.1%	-19.2%
Profitability
Gross Margin (TTM)	69.2%	0.0%
Operating Margin (TTM)	28.9%	0.0%
EBITDA Margin (TTM)	30.8%	-275.3%
Net Margin (TTM)	23.5%	-395.2%
FCF Margin (TTM)	9.5%	-318.6%
Net Income (TTM)	$19M	$-181M
FCF (TTM)	$8M	$-146M
EPS (TTM)	$0.23	-$10.90
ROE (TTM)	31.6%	-22384.0%
ROA (TTM)	20.1%	-8812.0%
ROIC (TTM)	31.6%	-22384.0%
Financial Health
Cash	$27M	$54M
Debt	$0	$239M
Net Cash/Debt	$27M	$-185M
Current Ratio (TTM)	2.94x	3.32x
Quick Ratio (TTM)	1.91x	3.22x
Debt/Equity (TTM)	0.00x	4.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.05	1.47
52W Performance	8.2%	67.2%
YTD Performance	59.8%	30.2%
% from 52W High	-12.9%	-67.5%
% from 52W Low	73.7%	99.6%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.22x
FCF Yield (TTM)	3.4%	-61.6%
Earnings Yield (TTM)	8.5%	-76.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	39.7	-374.9
EV/GP/RG	N/A	N/A
Ticker research	View PLX research	View STRO research